Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) announced the initiation of a collaborative research program with Viatar CTC Solutions Inc. (Viatar), the cancer dialysis company.
The collaboration utilizes Viatar’s novel circulating tumor cell collection technology in combination with the Company’s commercialized PancraGEN™ assay that is used to help assess indeterminate pancreatic cancer biopsies in patients with pancreatic cysts. Studies are being designed to identify patients most likely to develop pancreatic cancer in the near future as well as to detect pancreatic cancer at its earliest stage of development.
These pre-clinical studies are expected to take place over the next six months and may lead to the implementation of early diagnostic testing and assessment for patients with pancreatic diseases and/or for those predisposed to the development of this aggressive and difficult to treat form of cancer most in need of early and accurate detection.
According to Jack E. Stover President & CEO of Interpace Diagnostics, “We are pleased to partner with Viatar, a company dedicated to CTC’s and in combination with our PancraGEN assay we are hopeful of providing early detection, prognosis and disease monitoring by way of liquid biopsies for pancreatic cancer at its earliest stage of detection.”
Shares of Interpace Diagnostics Group Inc. closed last Friday at $2.72, up $0.06 or 2.26%. IDXG has a 1-year high of $19.80 and a 1-year low of $0.70. The stock’s 50-day moving average is $4.45 and its 200-day moving average is $1.36.
Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.